Test Price
2,800 AED✅ Home Collection Available
GALNT3 Gene Genetic Test for Tumoral Calcinosis, Hyperphosphatemic, Familial, Type 1 in UAE
Executive Summary & Core Metrics
Accuracy Guarantee: 99.9% diagnostic sensitivity achieved through ISO‑accredited NGS processing.
Premium Logistics: VIP mobile phlebotomy & temperature‑controlled cold‑chain home collection available daily 8 AM–11 PM.
Clinical Guidance: Telephonic post‑test genetic counselling by our Consultant Medical Geneticist.
Insurance Verification: WhatsApp +971 54 548 8731 for direct coverage checks.
Test Overview & Methodology
This next‑generation sequencing (NGS) test analyses the entire GALNT3 gene to diagnose hyperphosphatemic familial tumoral calcinosis type 1 – a rare metabolic bone disorder. Full‑gene sequencing with copy‑number detection provides comprehensive diagnostic confirmation.
| Feature | Our Test – GALNT3 NGS (Sequencing) | Closest Alternative – Targeted PCR Panel |
|---|---|---|
| Precision & Coverage | Full‑gene NGS with copy‑number & variant detection; analytical sensitivity >99% | Limited to hotspot mutations only; may miss rare variants |
| Methodology | Next‑Generation Sequencing (Illumina® platform) with bioinformatics confirmation | PCR‑based Sanger sequencing of selected exons |
| Turnaround Time | 3–4 weeks | 4–6 weeks (dependent on batch analysis) |
| Clinical Utility | Suitable for index case, carrier screening, and family testing | May require reflex to NGS if initial panel negative |
Physician Insight & Safety Protocols
“The GALNT3 genetic test is the gold standard for confirming hyperphosphatemic familial tumoral calcinosis type 1. However, it must always be interpreted alongside serum phosphate and FGF23 levels as well as imaging. A positive result enables early dietary phosphate restriction and medical therapy, yet a negative result does not exclude the diagnosis if clinical suspicion is high. Correlation with metabolic and radiological findings is essential for a sound management plan.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403
Important Safety Advisory
Do not discontinue any prescribed phosphate‑lowering medications (e.g., sevelamer, acetazolamide) without consulting your treating physician. Abrupt cessation may worsen hyperphosphataemia and calcification risk.
Exclusion Criteria & Emergency Red Flags
- This test is not for emergency diagnosis. Acute hypercalcaemic crises or severe joint pain require immediate emergency department evaluation.
- Patients under 18 years must have the requisition signed by a legal guardian, in compliance with Federal Decree‑Law No. 4 of 2016 on Medical Liability.
- If you experience sudden neurological symptoms (seizures, confusion) or visual disturbances, seek emergency care without delay – do not wait for genetic results.
- Individuals without a clinical or family history suggestive of tumoral calcinosis should first undergo metabolic and imaging evaluation before genetic testing.
Patient FAQ & Clinical Guidance
1. What is the GALNT3 gene test used for?
This NGS test identifies mutations in the GALNT3 gene that cause hyperphosphatemic familial tumoral calcinosis type 1, providing a definitive molecular diagnosis.
2. Why does the test cost 2800 AED?
The 2800 AED price includes whole‑gene NGS sequencing, expert bioinformatics analysis, a comprehensive clinical report, and a pre‑test genetic counselling session.
3. What sample is required and how quickly are results available?
Acceptable samples include whole blood, extracted DNA, or a single drop of blood on an FTA card. Results are reported within 3–4 weeks from sample receipt.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance
All genetic testing and data handling are conducted in full compliance with:
- Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) – ensuring patient genetic data privacy.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – governing secure electronic health records and telemedicine.
- Federal Decree‑Law No. 4 of 2016 on Medical Liability – governing clinical testing safety and informed consent.
ISO 9001:2015 Certified Facility (Cert: INT/EGQ/2509DA/3139) | DHA Facility License No. 1143
Clinical & Logistical Metadata
| Test Name | GALNT3 Gene NGS Sequencing – Hyperphosphatemic Familial Tumoral Calcinosis Type 1 |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Whole blood (3–5 mL in EDTA tube), extracted DNA, or FTA card blood spot |
| Methodology Used | Next‑Generation Sequencing (Illumina®), bioinformatics variant confirmation |
| ICD‑10‑CM Code | E83.51 (Hyperphosphatemia), E83.59 (Other disorders of phosphate metabolism) |
| LOINC Code | 82443-0 (GALNT3 gene mutation analysis in blood by NGS) |
| DHA Facility License & Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians